Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Pediatr Infect Dis J. 2008 Aug; 27(8):724-30.PI

Abstract

BACKGROUND

Measles, mumps, and rubella (MMR) and varicella (V) vaccines are often coadministered at 1 clinic visit. This study (104389/NCT00127023) was undertaken to assess the immunogenicity and safety of a new refrigerator-stable tetravalent MMRV vaccine after 1 dose and after 2 doses administered during the second year of life.

METHODS

Nine hundred seventy healthy children aged 10-21 months received 2 doses of MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals, Rixensart, Belgium) 42 days apart (MMRV group; N = 732) or 1 dose of MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) followed by a second dose of only MMR vaccine 42 days later (MMR + V group; N = 238).

RESULTS

Observed seroconversion rates for measles, mumps, rubella, and varicella antibodies 42 days postdose 1 were 94.5%, 96.1%, 99.7%, 95.5% in the MMRV group and 93.4%, 93.6%, 98.1%, 95.6% in the MMR + V group. Respective seroconversion rates postdose 2 were 98.3%, 99.4%, 99.7%, 99.7% in the MMRV group and 97.6%, 99.5%, 100%, 97.5% in the MMR + V group. Observed antimeasles and antimumps geometric mean titers (GMTs) were higher after each dose in the MMRV group than in the MMR + V group. Antivaricella GMT increased 21-fold in the MMRV group postdose 2, and was markedly higher than in the MMR + V group who did not receive a second dose of varicella (1903.3 and 80.3 dilution, respectively). Both vaccine regimens were generally well-tolerated in terms of local reactions, fever >39.5 degrees C, and vaccine-related rashes.

CONCLUSIONS

Both after 1 dose and after 2 doses, the MMRV vaccine was at least as immunogenic as concomitant MMR and varicella vaccination suggesting that it could be suitable for use according to current vaccination schedules.

Authors+Show Affiliations

Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany. volker.schuster@medizin.uni-leipzig.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18600190

Citation

Schuster, Volker, et al. "Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-stable Tetravalent Measles-mumps-rubella-varicella Vaccine in Healthy Children During the Second Year of Life." The Pediatric Infectious Disease Journal, vol. 27, no. 8, 2008, pp. 724-30.
Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27(8):724-30.
Schuster, V., Otto, W., Maurer, L., Tcherepnine, P., Pfletschinger, U., Kindler, K., Soemantri, P., Walther, U., Macholdt, U., Douha, M., Pierson, P., & Willems, P. (2008). Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. The Pediatric Infectious Disease Journal, 27(8), 724-30. https://doi.org/10.1097/INF.0b013e318170bb22
Schuster V, et al. Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-stable Tetravalent Measles-mumps-rubella-varicella Vaccine in Healthy Children During the Second Year of Life. Pediatr Infect Dis J. 2008;27(8):724-30. PubMed PMID: 18600190.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. AU - Schuster,Volker, AU - Otto,Walter, AU - Maurer,Lothar, AU - Tcherepnine,Patricia, AU - Pfletschinger,Ulrich, AU - Kindler,Klaus, AU - Soemantri,Peter, AU - Walther,Uta, AU - Macholdt,Ute, AU - Douha,Martine, AU - Pierson,Patrice, AU - Willems,Paul, PY - 2008/7/5/pubmed PY - 2008/9/9/medline PY - 2008/7/5/entrez SP - 724 EP - 30 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 27 IS - 8 N2 - BACKGROUND: Measles, mumps, and rubella (MMR) and varicella (V) vaccines are often coadministered at 1 clinic visit. This study (104389/NCT00127023) was undertaken to assess the immunogenicity and safety of a new refrigerator-stable tetravalent MMRV vaccine after 1 dose and after 2 doses administered during the second year of life. METHODS: Nine hundred seventy healthy children aged 10-21 months received 2 doses of MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals, Rixensart, Belgium) 42 days apart (MMRV group; N = 732) or 1 dose of MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) followed by a second dose of only MMR vaccine 42 days later (MMR + V group; N = 238). RESULTS: Observed seroconversion rates for measles, mumps, rubella, and varicella antibodies 42 days postdose 1 were 94.5%, 96.1%, 99.7%, 95.5% in the MMRV group and 93.4%, 93.6%, 98.1%, 95.6% in the MMR + V group. Respective seroconversion rates postdose 2 were 98.3%, 99.4%, 99.7%, 99.7% in the MMRV group and 97.6%, 99.5%, 100%, 97.5% in the MMR + V group. Observed antimeasles and antimumps geometric mean titers (GMTs) were higher after each dose in the MMRV group than in the MMR + V group. Antivaricella GMT increased 21-fold in the MMRV group postdose 2, and was markedly higher than in the MMR + V group who did not receive a second dose of varicella (1903.3 and 80.3 dilution, respectively). Both vaccine regimens were generally well-tolerated in terms of local reactions, fever >39.5 degrees C, and vaccine-related rashes. CONCLUSIONS: Both after 1 dose and after 2 doses, the MMRV vaccine was at least as immunogenic as concomitant MMR and varicella vaccination suggesting that it could be suitable for use according to current vaccination schedules. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/18600190/Immunogenicity_and_safety_assessments_after_one_and_two_doses_of_a_refrigerator_stable_tetravalent_measles_mumps_rubella_varicella_vaccine_in_healthy_children_during_the_second_year_of_life_ L2 - https://doi.org/10.1097/INF.0b013e318170bb22 DB - PRIME DP - Unbound Medicine ER -